UNC Health

     System Formulary Restriction:

     Epcoritamab-bysp injection orders must be signed by a Hematology/Oncology Attending Physician  

     Inpatient use of epcoritamab-bysp injection is restricted to patients who meet one of the following criteria:

• Initiation/new-start treatment for relapsed/refractory diffuse large B-cell lymphoma
• Re-initiation of treatment in patients with relapsed/refractory diffuse large B-cell lymphoma who have experienced a treatment delay that requires re-initiation with step-up doses 

     All other use is restricted to outpatient encounters or clinic use only (ie, no inpatient use)

• Lexicomp
• Micromedex
• UpToDate
• FDA Daily Med